Janus Henderson Group PLC Purchases Shares of 13,605 Pfenex Inc (NYSEAMERICAN:PFNX)

Share on StockTwits

Janus Henderson Group PLC purchased a new stake in Pfenex Inc (NYSEAMERICAN:PFNX) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 13,605 shares of the biotechnology company’s stock, valued at approximately $91,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. RK Capital Management LLC acquired a new position in Pfenex in the 1st quarter valued at approximately $1,864,000. Millennium Management LLC increased its position in shares of Pfenex by 496.1% during the fourth quarter. Millennium Management LLC now owns 75,364 shares of the biotechnology company’s stock worth $240,000 after buying an additional 62,722 shares during the period. Dimensional Fund Advisors LP increased its position in shares of Pfenex by 4.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 676,046 shares of the biotechnology company’s stock worth $2,157,000 after buying an additional 31,132 shares during the period. Bank of New York Mellon Corp increased its position in shares of Pfenex by 16.9% during the fourth quarter. Bank of New York Mellon Corp now owns 95,602 shares of the biotechnology company’s stock worth $305,000 after buying an additional 13,795 shares during the period. Finally, Northern Trust Corp increased its position in shares of Pfenex by 0.8% during the fourth quarter. Northern Trust Corp now owns 327,376 shares of the biotechnology company’s stock worth $1,045,000 after buying an additional 2,726 shares during the period.

Pfenex stock opened at $7.25 on Thursday. Pfenex Inc has a 1-year low of $3.13 and a 1-year high of $7.64.

Pfenex (NYSEAMERICAN:PFNX) last announced its earnings results on Thursday, August 8th. The biotechnology company reported ($0.24) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.31) by $0.07. The firm had revenue of $2.81 million during the quarter, compared to analysts’ expectations of $5.65 million.

Separately, Zacks Investment Research raised shares of Pfenex from a “hold” rating to a “buy” rating and set a $7.75 target price on the stock in a research note on Thursday, August 15th.

Pfenex Profile

Pfenex Inc, a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study.

Read More: Yield Curve

Institutional Ownership by Quarter for Pfenex (NYSEAMERICAN:PFNX)

Receive News & Ratings for Pfenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfenex and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Hartwell J M Limited Partnership Boosts Stock Holdings in Microsoft Co.
Hartwell J M Limited Partnership Boosts Stock Holdings in Microsoft Co.
Microsoft Co.  Stock Holdings Increased by Waldron Private Wealth LLC
Microsoft Co. Stock Holdings Increased by Waldron Private Wealth LLC
Microsoft Co.  is Merriman Wealth Management LLC’s Largest Position
Microsoft Co. is Merriman Wealth Management LLC’s Largest Position
Microsoft Co.  Shares Sold by Sheaff Brock Investment Advisors LLC
Microsoft Co. Shares Sold by Sheaff Brock Investment Advisors LLC
Senseonics Holdings Inc  Shares Sold by Janus Henderson Group PLC
Senseonics Holdings Inc Shares Sold by Janus Henderson Group PLC
13,042 Shares in SRC Energy Inc  Acquired by Janus Henderson Group PLC
13,042 Shares in SRC Energy Inc Acquired by Janus Henderson Group PLC


© 2006-2019 Ticker Report